10-Q: Collegium Pharma Q1 2026 Revenue Up, AZSTARYS Deal Nears

Collegium Pharmaceutical reported a 9% increase in Q1 2026 revenue to $193.5 million, driven by strong performance in Jornay PM and Xtampza ER, while nearing the completion of its AZSTARYS acquisition.

Summary

• Collegium Pharmaceutical reported a 9% year-over-year increase in product revenues for the first quarter of 2026, reaching $193.5 million compared to $177.8 million in the prior year period.
• The growth was primarily attributed to higher revenues from Jornay PM ($10.4 million increase), Xtampza ER ($3.1 million increase), Symproic ($1.4 million increase), and Belbuca ($1.0 million increase).
• Net income for the quarter was $14.5 million, a significant increase from $2.4 million in the first quarter of 2025.
• The company announced its intention to acquire AZSTARYS for $650 million in cash, with the transaction expected to close in the second quarter of 2026.
• Operating expenses increased by $10.0 million, largely due to acquisition-related expenses for AZSTARYS and increased salaries, wages, and benefits.
• Adjusted EBITDA increased by 9.2% to $103.9 million, reflecting improved operational performance.
• The company ended the quarter with $421.8 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth and improved profitability, offset by increased operating expenses related to the upcoming acquisition and ongoing legal matters.

Positives

• Product revenues increased by 9% to $193.5 million in Q1 2026, driven by strong performance in key products.
• Jornay PM revenue increased by $10.4 million due to higher sales volume, lower gross-to-net adjustments for co-pay incentives, and higher gross price.
• Xtampza ER revenue increased by $3.1 million due to higher gross price and lower gross-to-net adjustments for rebates.
• Symproic revenue increased by $1.4 million due to lower gross-to-net adjustments for product returns, higher gross price, and higher sales volume.
• Belbuca revenue increased by $1.0 million due to higher gross price and higher sales volume.
• Net income saw a substantial increase to $14.5 million from $2.4 million in the prior year quarter.
• Adjusted EBITDA grew by 9.2% to $103.9 million, indicating improved profitability.
• The company ended the quarter with a strong liquidity position of $421.8 million in cash, cash equivalents, and marketable securities.

Negatives

• Selling, general, and administrative expenses increased by $10.0 million, primarily due to acquisition-related expenses for AZSTARYS and increased personnel costs.
• Cost of product revenues (excluding intangible asset amortization) decreased by $4.2 million, partly due to a $3.5 million inventory step-up in the prior year quarter.
• The company faces ongoing litigation related to patent infringement for Xtampza ER and Nucynta, as well as other legal proceedings.
• The company has substantial outstanding indebtedness, including a $572.8 million term loan and $241.5 million in convertible senior notes.

Risks

• The announcement and pendency of the AZSTARYS acquisition may adversely affect business, financial condition, operating results, and cash flows.
• Failure to successfully integrate AZSTARYS could prevent the realization of anticipated benefits.
• The company relies on third-party manufacturers, and any production issues or supply chain disruptions could materially impact its business.
• Ongoing litigation, including patent infringement cases and opioid-related investigations, could result in significant costs and adverse outcomes.
• The company's products are subject to stringent government regulations, including REMS programs for opioid products, and failure to comply could lead to sanctions.
• Competition from other pharmaceutical companies and the potential approval of generic products could negatively impact sales.
• Changes in healthcare laws and regulations, including pricing and reimbursement policies, could adversely affect the business.
• The company's significant outstanding indebtedness could limit its financial flexibility and increase its vulnerability to economic downturns.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities, along with expected cash inflows from operations, will be sufficient to fund its operating expenses, debt service, and capital expenditure requirements for the foreseeable future. However, the company anticipates significant future capital requirements related to ongoing operations, debt repayment, and potential business development transactions.

Management Comments

• The company's mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.
• The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain.
• The company plans to defend its intellectual property rights vigorously against Alvogen and Chemo Research, S.L.
• The company intends to vigorously defend against the claims in the North Sound Pharmaceuticals arbitration.
• Collegium intends to vigorously defend against the claims in the Walgreen Co. lawsuit.

Industry Context

StockSavvy.ai notes that Collegium Pharmaceutical's Q1 2026 results reflect continued growth in the ADHD and pain management markets, with a notable increase in revenue driven by its key products. The planned acquisition of AZSTARYS signals a strategic move to further strengthen its position in the neuropsychiatry space, particularly for ADHD treatments, aligning with broader industry trends of portfolio expansion and diversification.

Legal Proceedings

• Ongoing patent infringement litigation related to Xtampza ER with Purdue, with a successor company expected to be substituted as plaintiff.
• Patent infringement lawsuit filed by Grnenthal GMBH against Collegium and Hikma Pharmaceuticals concerning Nucynta ER authorized generic launch.
• Opioid-related investigations and subpoenas from state attorneys general, with an Assurance of Discontinuance entered with the Massachusetts Attorney General.
• Litigation related to the BDSI Acquisition, which has seen dismissals of several cases.
• Patent infringement litigation against Alvogen concerning Belbuca, with ongoing appeals and new notice letters.
• Patent infringement litigation against Chemo Research, S.L. concerning Belbuca, with ongoing FDA complete response letters.
• Request for Arbitration filed by David Lickrish, legal assignee of North Sound Pharmaceuticals, Inc., against Ironshore Pharmaceuticals & Development, Inc.
• Lawsuit filed by Walgreen Co. alleging credits owed for returned products, refiled in Massachusetts after dismissal for lack of personal jurisdiction.

Stakeholder Impact

• Shareholders may benefit from increased revenue and net income, but face risks associated with the AZSTARYS acquisition and ongoing litigation.
• Employees may be impacted by increased headcount and potential integration activities related to the AZSTARYS acquisition.
• Customers (wholesalers, pharmacies) will continue to receive products, with potential impacts from supply chain management.
• Creditors may be affected by the company's substantial outstanding indebtedness.

Next Steps

• Complete the acquisition of AZSTARYS in the second quarter of 2026.
• Continue to commercialize and grow sales of existing products, including Jornay PM, Belbuca, Xtampza ER, and the Nucynta Products.
• Manage ongoing litigation and regulatory matters.
• Continue to monitor and manage supply chain and manufacturing operations.

Key Dates

Recommendation

Collegium Pharmaceutical shows strong revenue growth and improved profitability, driven by key product performance. However, the significant increase in operating expenses due to the upcoming AZSTARYS acquisition, coupled with ongoing litigation and substantial debt, introduces considerable risk. While the acquisition is strategically sound for market expansion, the integration challenges and potential legal liabilities warrant a cautious approach. Therefore, a 'hold' recommendation is appropriate, pending clearer visibility on the successful integration of AZSTARYS and resolution of legal matters.

Keywords

Collegium Pharmaceutical, Form 10-Q, Quarterly Report, Jornay PM, Belbuca, Xtampza ER, Nucynta, Symproic, ADHD, Pain Management, AZSTARYS Acquisition, Financial Results, Revenue Growth, Earnings Per Share, Adjusted EBITDA